Why Ultragenyx Pharma (RARE) Shares Are Trading Higher Today - Ultragenyx Pharmaceutical (NASDAQ:RARE)

Ultragenyx Pharmaceutical Inc's RARE Q2 sales reached $89.3 million, up from $86.97 million a year ago, beating the consensus of $87.51 million.
The company recognized $64.0 million in Crysvita (burosumab) revenue in the Ultragenyx territories, including $51.6 million in collaboration revenue in the North American profit share territory and net product sales in other territories regions of $12.4 million.
Yoyalty revenue related to European Crysvita sales was $5.4 million.
Dojolvi's (triheptanoin) product sales were $13.5 million. Mepsevii (vestronidase alfa) product sales were $4.9 million.
Related: Ultragenyx Sells One-Third Of Future North American Crysvita Royalties For $500M.
The company reported an EPS loss of $(2.26), higher than $(1.81) a year ago and better than the consensus of $(1.75).
As of June 30, 2022, cash, cash equivalents, and marketable debt securities were $706.1 million.
Guidance: The company continues to expect FY22 revenue for Crysvita in Ultragenyx territories of $250 million - $260 million and Dojolvi revenue of $55 million - $65 million.
Price Action: RARE shares are up 4.66% at $54.30 during the market session on the last check Friday.

Ultragenyx Pharma Posts Smaller Than Expected Q2 Loss, Reaffirms Guidance